| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
23072 |
| Drug |
Zanubrutinib |
| Brand |
Brukinsa® |
| Indication |
Zanubrutinib monotherapy is indicated for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. |
| Rapid review commissioned |
01/12/2023 |
| Rapid review completed |
09/01/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of zanubrutinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/01/2024 |
| Pre-submission consultation with Applicant |
12/03/2024 |
| Full submission received from Applicant |
20/08/2024 |
